China Biologic Products Holdings, Inc. announced that its board of directors (the “Board”) has formed a special committee (the “Special Committee”) to review and evaluate the previously announced preliminary non-binding “going private” proposal that the Board received on September 18, 2019 from Beachhead Holdings Limited, CITIC Capital China Partners IV, L.P., PW Medtech Group Limited, Parfield International Ltd., HH Sum-XXII Holdings Limited and V-Sciences Investments Pte. Ltd. The Special Committee is composed of Mr. Sean Shao, Dr. Yungang Lu and Mr. Qi Ning, who are independent directors of the Company and are unaffiliated with the Proposal. Mr. Sean Shao will be the chairman of the Special Committee.